The Medigene Share
The Medigene share MDG1 (ISIN:DE000A1X3W00 ) is listed at the Frankfurt Stock Exchange since June 2000.
Investors & Media
Welcome to the Investor Relations and Public Relations division of Medigene AG. This is where you will find current information on a variety of subjects, including Medigene AG shares, company news, financial reports and key figures.
Events
20 - 21
Jan 2021
5th Annual Onco Cell Therapy Summit
08 - 12
Feb 2021
TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
16 - 18
Feb 2021
CAR-TCR Europe
23 - 25
Feb 2021
Immuno-Oncology 360°
25
Mar 2021
Annual Report 2020
11
May 2021
Quarterly Statement Q1 2021
08 - 10
Jun 2021
TCR-Based Therapies Summit
24
Jun 2021
Annual General Meeting 2021
12
Aug 2021
6-Month Report 2021
Corporate Governance
Good corporate governance is the basis of our decision-making and monitoring processes. It stands for responsible and value-based leadership and control of the Company for long-term success, goal-oriented and efficient cooperation between the Executive Board and Supervisory Board, respect for the interests of our shareholders and employees, consistently transparent and responsible corporate decisions and an appropriate risk management system.
Contact person
Dr Gary Waanders
Vice President Investor Relations
investor(at)medigene.com
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20
Dr. Anna Niedl
Director Investor Relations
investor(at)medigene.com
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20